MARK4 polyclonal (C-term), anti-human

Background:
MARK4 contains an N-terminal serine/threonine kinase domain, a central ubiquitin-associated domain, and a C-terminal KA1-associated kinase domain. RT-PCR analysis detects upregulated expression of the gene for MARK4 in nearly all clinical hepatocellular carcinoma cells. Northern blot analysis reveals ubiquitous expression of a 3.6-kb transcript, with highest expression in testis. Immunofluorescence microscopy demonstrates homogeneous cytoplasmic expression. Colony-forming assays show that MARK4 antisense reduces the growth of SNU475 cells. It has been suggested that MARK4 provides a growth advantage to cells.

Other Names:
MAP/microtubule affinity-regulating kinase 4, MAP/microtubule affinity-regulating kinase-like 1, MARK4, KIAA1860, MARKL1

Target/Specificity:
This MARK4 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 611-641 amino acids from the C-terminal region of human MARK4.

Antigen Region:
611-641

Antigen Type: Synthetic Peptide

Gene Name: MARK4 {ECO:0000303|PubMed:14594945, ECO:0000312|HGNC:HGNC:13538}
Gene ID: 57787
Primary Accession: Q96L34
NCBI Accession: NP_001186796.1;NP_113605.2
Format: Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.